Clinical Trials
The Morgan Welch Inflammatory Breast Cancer Research Program is committed to finding what causes inflammatory breast cancer and identifying new treatment options. We are conducting a number of treatment-based studies and a wide variety of lab based studies to understand this disease better.
Tumor Registry
Protocol 2006-1072: Inflammatory Breast Cancer (IBC) – N. Ueno
The goal of this research study is to collect blood, tissue samples and clinical data from patients with untreated newly diagnosed inflammatory breast cancer (Cohort 1) and previously treated IBC (Cohort 2). Any MD Anderson patient with IBC may participate. If you would like to commit your tissue to this registry please contact Jie Willey, MSN, 713-792-3965. Your tissue is precious and critical to curing this disease. With your consent, your tumor tissue will be banked and will be used for critical IBC research that has been approved by the MDACC institutional review board to ensure you are protected and the science is sound. Your privacy will be maintained at all times and you have the right to withdraw your consent at any time. Withdrawing consent to use the tissue or moving it to another research program is your right but can be detrimental to ongoing research, so please consider your decision to enter or leave any registry carefully.
Clinical Trials
Updated 1/18/12
For information about enrolling in clinical trials contact Jie Willey, MSN, 713-792-3965.
- 2007-0818: Phase II Study of Neoadjuvant Lapatinib plus Chemotherapy (sequential FEC75 and Paclitaxel) in Women with Inflammatory Breast Cancer Whose Tumors Overexpress ErbB2 (her2/neu) – R Alvarez (Closed to Patent Enrollment)
- 2008-0372: Phase II Study of Panitumumab, Nab-paclitaxel, and Carboplatin for Patients with Primary Inflammatory Breast Cancer (IBC) without HER2 Overexpression - N Ueno
- NSABPFB-7: A Phase II randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel and Neratinib or Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2 Positive Breast Cancer - V Valero
- 2010-0296: A Phase II Study of TKI258 (Dovitinib Lactate) as Salvage Therapy in Patients with First Local or Distant Relapse HER2-negative Inflammatory Breast Cancer (IBC) (up to 2 prior therapy). R Alvarez
- 2010-0683: A randomized, phase II, multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of metmab in combination with Paclitaxel in patients with metastatic, triple-negative breast cancer. V Valero
- 2010-0696: A phase I/II study to evaluate the safety, tolerability, and preliminary efficacy of KW-2450 in combination with lapatinib and letrozole in subjects with advanced or metastatic breast cancer whose tumor overexpress HER2 - N Ueno
- 2010-0842: Phase I/II Study of Entinostat and Lapatinib in Patients with HER2-Positive Metastatic Breast Cancer in Whom Trastuzumab has Failed. N Ueno
Phase I Studies
MD Anderson has a program dedicated to the latest cutting edge therapies in testing. The Clinical Center for Targeted Therapy conducts innovative Phase I trials (early drug trials) with new drugs that may eventually improve the management of cancer. It doesn’t mean there are no other chemotherapies you can use, in fact, it's just the opposite! It usually means you are in good shape and might be a better candidate for one of the newer, more targeted therapies rather than traditional therapies.
Stem Cell Transplant
For a certain population of patients, after completing their initial therapy or have responding metastatic disease, stem cell transplant may be option with the goal to reduce the chance of recurrence.